Investor Presentaiton
sanofi
Favorable PCV21 immune responses when compared to PCV20
Serotypes shared with PCV20 or unique to PCV21
IgG GMC ratio and difference % seroresponse vs lowest in PCV13 group
Post Dose 3: IgG GMC ratio
Post Dose 3: Difference seroresponse
Post Dose 4: IgG GMC ratio
8
NG
9N
10A
11A
12F
15B
22F
HHH
K
33F
HH
0,25 0.5
1
4
8
9N
10A
11A
12F
15B
22F
33F
16
-30
-10
10
8
9N
N
10A
11A
12F
15B
22F
33F
30
0,25
0.5
1
4
16
PCV21 Phase II [NCT04398706] Seroresponse: IgG concentration ≥0.35 μg/mL for all serotypes
PCV20 Phase III [NCT04382326] Seroresponse: IgG concentration ≥0.35 μg/mL for all serotypes except ≥ 0.23 µg/mL, 20.10 µg/mL and ≥ 0.12 µg/mL for serotypes 5, 6B and 19A respectively
Note: difference (% and GMC ratio) vs lowest serotype in PCV 13
PCV21 selected formulation for next phase DISCLAIMER: data from separate studies should be interpreted with care.
65 Vaccines Investor Event
PCV21 Phase 2
PCV20 Phase 3
Registration
criteria based
on PCV13View entire presentation